Charles River Laboratories International, Inc. (CRL) News
Track canonical SquawkNews coverage tagged to CRL, Charles River Laboratories International, Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 22 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CRL - Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
CRL - Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
NEWS | Sep 17, 2026, 12:03 PM UTC
L
CRL: Strong bookings, operational modernization, and supply chain investments drive margin growth
Leadership transition has been smooth, with a renewed focus on modernization and client-centric growth. Strong financial performance is supported by robust bookings and backlog recovery, while operational improvements an
NEWS | Sep 15, 2026, 03:54 PM UTC
L
CRL: Leadership transition and strategic execution are fueling growth, margin expansion, and operational resilience
New leadership is driving a strategy focused on modernization, operational efficiency, and client-centric growth, with strong recent financial performance and improved margins. Investments in supply chain and portfolio o
NEWS | Sep 15, 2026, 02:49 PM UTC
L
CRL - Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
CRL - Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
EQUITY | Sep 08, 2026, 12:06 PM UTC
L
Charles River implements automated Endosafe cartridge manufacturing suite
Charles River Laboratories International implemented its Endosafe Cartridge Technology Automated Manufacturing Suite to expand in-process inspection and digital traceability for bacterial endotoxin testing cartridge prod
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Charles River Laboratories partners with Medigen on sequencing programs
Charles River Laboratories (CRL) and Medigen Vaccine Biologics Corp collaborate to advance new vaccine development programs through next generation sequencing.
MNA | Aug 20, 2026, 12:08 PM UTC
L
Charles River Laboratories, Medigen Vaccine Biologics Collaborate on Vaccine Programs
Charles River Laboratories and Medigen Vaccine Biologics Corp collaborate to advance new vaccine development programs through next-generation sequencing.
MNA | Aug 20, 2026, 12:01 PM UTC
H
Citrini Initiates Long Position
Citrini takes long position
EQUITY | Aug 10, 2026, 05:01 PM UTC
H
JPM Upgrades CRL To Overweight
JPM upgrades CRL to overweight
EQUITY | Aug 06, 2026, 11:28 AM UTC
H
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
Gold ripped 4% higher to $4,233.89 an ounce on Wednesday, its biggest one-day advance since February, as a soft private payrolls report and easing energy costs knocked down the odds of another Federal Reserve rate hike.
EARNINGS | Aug 05, 2026, 06:14 PM UTC
H
Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
Charles River Laboratories International Inc. (NYSE: CRL ) stock traded higher Wednesday after the contract research organization raised its full-year 2026 financial guidance following second-quarter results that exceede
EARNINGS | Aug 05, 2026, 06:03 PM UTC
H
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Wednesday. Shares of Wynn Resorts Ltd (NASDAQ: WYNN ) rose sharply after the company reported better-than- expected quarterly financial resul
EARNINGS | Aug 05, 2026, 02:01 PM UTC
H
Shopify Beats Revenue Estimates
Shopify reports revenue beat
EARNINGS | Aug 05, 2026, 11:07 AM UTC
H
Charles River Raises FY2026 Adj EPS Guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 Est; Raises FY2026 Sales Guidance from $3.794B-$3
Charles River (NYSE: CRL ) raises FY2026 Adj EPS guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 analyst estimate. Raises FY2026 sales outlook from $3.794 billion-$3.854 billion to $3.879 billion-$3.920 billion vs
EARNINGS | Aug 05, 2026, 11:02 AM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
H
IQV shares +10% premarket after results and guidance as raises FY2026 adj EPS forecast to $12.80-$13.00 from prior forecast of $12.65-$12.95
IQV shares +10% premarket after results and guidance as raises FY2026 adj EPS forecast to $12.80-$13.00 from prior forecast of $12.65-$12.95as midpoint tops ests $12.90; posted Q2 EPS and rev beat $4.37B vs. est. $4.3B -
EARNINGS | Jul 28, 2026, 12:48 PM UTC
L
moves among today's downgrades PENG -11.4%, FNB -2.6%, CRL -2.5%, BIRK -2.2%, FDUS -2.1%, HUBS -1.7%, ATAI -1.3%, TFC -1.2%, SCHW -0.4%, MNS
moves among today's downgrades PENG -11.4%, FNB -2.6%, CRL -2.5%, BIRK -2.2%, FDUS -2.1%, HUBS -1.7%, ATAI -1.3%, TFC -1.2%, SCHW -0.4%, MNST +0.3%, ALGM +2.9%, SNEX +3.2% moves among today's negative initiations WDAY -1
EQUITY | Jul 20, 2026, 01:43 PM UTC
L
CRL downgraded from Outperform to Hold W/ $219 PT @ CLSA
CRL downgraded from Outperform to Hold W/ $219 PT @ CLSA
EQUITY | Jul 20, 2026, 12:20 PM UTC
L
CRL Downgrade from Outperform (2) to Hold (3) W/$219.00 PT at CLSA
CRL Downgrade from Outperform (2) to Hold (3) W/$219.00 PT at CLSA
EQUITY | Jul 20, 2026, 11:49 AM UTC
L
ACHV Cytisinicline's CRL was released by FDA, and no surprises with Q426 resubmission still planned; BUY, $13 PT @ Canaccord
ACHV Cytisinicline's CRL was released by FDA, and no surprises with Q426 resubmission still planned; BUY, $13 PT @ Canaccord
REGULATION | Jul 14, 2026, 12:17 PM UTC
H
Charles River price target raised to $260 from $220 at Morgan Stanley
Morgan Stanley raised the firm's price target on Charles River to $260 from $220 and keeps an Overweight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 10:57 AM UTC
L
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Charles River Laboratories International, Inc. Insi
EQUITY | Jul 03, 2026, 04:25 PM UTC